Page last updated: 2024-12-06
6-azacytosine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
6-azacytosine: 3-amino-1,2,4-triazin-5(2H)-one is an isosteric isomer of isocytosine; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 70265 |
SCHEMBL ID | 195844 |
MeSH ID | M0119045 |
Synonyms (25)
Synonym |
---|
5-amino-1,2,4-triazin-3(2h)-one |
nsc132918 |
nsc-132918 |
931-85-1 |
6-azacytosine |
5-amino-2h-1,2,4-triazin-3-one |
1,2,4-triazin-3(2h)-one, 5-amino- |
AKOS002260752 |
AKOS003242136 |
nsc 132918 |
einecs 213-241-3 |
FT-0633128 |
F3097-0463 |
SCHEMBL195844 |
SVXNJCYYMRMXNM-UHFFFAOYSA-N |
5-imino-4,5-dihydro-1,2,4-triazin-3(2h)-one # |
5-amino-as-triazine-3(2h)-one |
DTXSID20239274 |
mfcd00023642 |
5-amino-2,3-dihydro-1,2,4-triazin-3-one |
5-imino-4,5-dihydro-1,2,4-triazin-3(2h)-one |
CS-0204989 |
phenothiazine-10-aceticacid |
SB73440 |
LS-06761 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 4 (57.14) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 2 (28.57) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.51
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.51) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |